Aberrant regulation of gene expression in cancer can promote survival and proliferation of cancer cells. Here we integrate whole-genome sequencing data from The Cancer Genome Atlas (TCGA) for 436 patients from 8 cancer subtypes with ENCODE and other regulatory annotations to identify point mutations in regulatory regions. We find evidence for positive selection of mutations in transcription factor binding sites, consistent with these sites regulating important cancer cell functions. Using a new method that adjusts for sample-and genomic locus-specific mutation rates, we identify recurrently mutated sites across individuals with cancer. Mutated regulatory sites include known sites in the TERT promoter and many new sites, including a subset in proximity to cancer-related genes. In reporter assays, two new sites display decreased enhancer activity upon mutation. These data demonstrate that many regulatory regions contain mutations under selective pressure and suggest a greater role for regulatory mutations in cancer than previously appreciated.
Cancer is the second leading cause of death in the United States 1 . As of 2009, approximately 40% of Americans will develop cancer in their lifetime, and approximately 50% of these individuals will die of their disease 2 . Despite substantial advances in understanding of the genetic causes of cancer, many therapeutic challenges remain. The complexity of cancer etiology and therapy stems from the fact that no two individuals' cancers are identical, as cancer arises from the selection of specific point mutations, structural variants and epigenetic alterations from a large pool of such variation.
To better understand the genetic causes of cancer, large-scale projects such as TCGA have performed comprehensive omics profiling of cancer and normal paired samples from thousands of individuals with diverse cancer types. These endeavors have focused primarily on exome sequencing, with more recent efforts involving whole-genome sequencing. Analysis of pan-cancer variation from exome sequencing identified shared sets of mutated genes and pathways among groups of cancer types. Furthermore, these studies have identified mutations in coding genes known as driver mutations that undergo positive selection in cancer 3 .
Although the majority of sequencing studies in cancer have focused on protein-coding sequences, only a small fraction of the genome encodes protein. Of the remaining genomic sequence, a large portion contains regulatory elements 4 . It is possible that driver mutations in regulatory elements exist that dysregulate oncogenes and tumor suppressors. Recently, an example of a regulatory mutation in cancer was identified in the regulatory region upstream of the TERT gene (encoding telomerase reverse transcriptase) 5, 6 . Furthermore, Weinhold et al. 7 identified recurrent regulatory mutations modulating the expression of PLEKHS1, WDR74 and SDHD in an analysis of mutations in promoters and enhancers. Fredriksson et al. 8 identified recurrent mutations in proximity to gene transcriptional start sites (TSSs), although only TERT mutations were significantly associated with altered mRNA transcript levels. Thus far, a genome-wide analysis of potential recurrent mutations in all annotated regulatory regions has yet to be performed.
The Encyclopedia of DNA Elements (ENCODE) Project is a National Human Genome Research Institute (NHGRI)-funded project with the goal of identifying all the functional elements in the human genome. As of 2012, this project assayed up to 12 histone modifications in 46 cell types and 119 different DNA-binding proteins across 72 cell types 4 . Additional data from this project include DNase I-hypersensitive sites, formaldehyde-assisted isolation of regulatory elements (FAIRE)-identified sequences, DNA methylation, chromosome-interacting regions and RNA transcription. These data and additional genome-wide data sets, including ones from the recent Roadmap Epigenomics Mapping Consortium (REMC) 9 , have been combined into database resources. One such resource, RegulomeDB 10 , provides regulatory annotations for any given position in the human genome, enabling facile annotation of regulatory features for potential disease-causing variants.
In this study, we analyze TCGA whole-genome sequencing data to define sets of point mutations for 436 cancer samples from 8 cancer types. We annotate the mutations with regulatory information and implement a statistical framework to define significantly mutated regulatory regions. We identify the previously observed mutations in the TERT promoter and numerous new mutated regulatory sites. This study indicates that there is a far greater role for regulatory region mutations in cancer than has been previously appreciated.
RESULTS

Identification of somatic mutations in cancer
To identify somatic cancer variants that reside in regulatory regions, we established a data processing workflow ( Fig. 1a) . We subjected whole-genome sequencing data generated from cancer and normal tissues collected from 436 patients to rigorous analysis to identify single-nucleotide variants (SNVs) using 2 different algorithms. To increase our power to detect recurrent variants, we analyzed all available patient data from eight different types of cancer ( Fig. 1a) . We performed additional filtering after mutation calling to remove mutations that were likely falsely called owing to mapping error (Online Methods and Supplementary Fig. 1 ). This filtering was performed using a heuristic method that searches for homologous genomic regions where a called variant is present in the reference sequence. Lastly, to aid in downstream statistical analyses, we divided our cancer samples into test and validation sets. These two sets were generated to have similar numbers of samples and similar distributions of number of mutations per sample ( Supplementary Fig. 1 ).
Summarizing mutation count data for the samples showed substantial variability between samples within cancer types and between cancer types ( Fig. 1b) , with a higher mutational load in the lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) samples, consistent with published data 11 . Mutation allele fractions differed slightly between cancer types, and this might reflect a difference in sample purity and/or clonogenicity ( Supplementary  Fig. 2a ). Mutation count was not correlated with sequencing depth, suggesting that the whole-genome samples were sequenced at sufficient coverage (median of 34-fold for normal and 50-fold for cancer tissues) to capture a majority of abundant somatic mutations ( Supplementary  Fig. 2b,c) . These data support the integrity of the set of highquality mutations.
Annotation of cancer mutations
To investigate the role of regulatory mutations, we annotated our mutation set with gene and regulatory information from GENCODE and RegulomeDB. RegulomeDB is a searchable database of publicly available regulatory data that includes a wealth of experimental data for transcription factors, epigenetic marks, motifs and DNA accessibility 10 . We used this database because it provides uniformly processed, high-quality annotations of known regulatory information for any given location in the human genome. For any given site, RegulomeDB provides a score between 1 and 7 in order of decreasing regulatory evidence. In addition to regulatory annotation, we performed transcript annotation using GENCODE transcripts. Of note, the potential false positive mutations due to mapping error filtered out of our analysis were highly enriched in non-regulatory regions ( Supplementary Fig. 1) , presumably owing to the fact that the excluded sites often fell in difficult-to-align genomic regions that are also filtered out in the ENCODE peak calling pipeline employed by RegulomeDB ( Supplementary Fig. 1) . Overall, the annotation procedures showed that mutations in coding exons and potential regulatory regions represent approximately 0.036-0.056% and 31-39% of the called mutations for each cancer type, respectively ( Fig. 2a,b) .
The large fraction of mutations that fall in putative regulatory regions underscores the potential for regulatory dysfunction in cancer.
Absence of purifying selection in regulatory regions
We next sought to investigate whether mutations in regulatory regions are globally subject to purifying selection in cancer. Purifying selection occurs to preserve the fidelity of regions important to the survival of the cell and manifests as fewer observed mutations in comparison to what is expected by chance. Previously, analysis showed that coding regions and regulatory elements are depleted for mutations when compared to intergenic, non-regulatory regions 7, 12 . These data could be explained by purifying selection or, alternatively, by correlation of regulatory elements with covariates known to affect mutation rate, including replication timing and base-pair composition 11 . To analyze purifying selection independently of these covariates, we compared the fraction of mutations in regulatory elements to a set of simulated mutations selected to have matched replication timing and base-pair composition and to have sufficient coverage such that they could have been called mutations in our analyses ( Supplementary Fig. 1 ). Comparing actual to simulated mutations in regulatory regions relative to non-regulatory regions showed little difference in mutation rate. The data actually showed a slight enrichment of mutations in regulatory regions, although the effect size was sufficiently small that this increase is unlikely to have functional consequences ( Fig. 2d,e) .
In parallel to our analysis of regulatory sites, we performed enrichment analysis of mutations in coding exons, coding introns, noncoding exons and noncoding introns ( Fig. 2c,e ). We similarly observed no consistent enrichment or depletion of mutations in coding exons or any other transcript category. This result is consistent with a previous study by Ostrow et al., which examined selective pressure in coding regions through the analysis of synonymous versus nonsynonymous mutation rates. Ostrow et al. found that, in comparison to germline variation, somatic variation in cancer is governed less by purifying selection and more by positive selection 13 .
Recurrent mutation across regulatory element binding sites
Analysis of categories of regulatory mutations based on RegulomeDB score identified some enriched categories and cancer type combinations; however, there was no consistent trend across all cancer types ( Fig. 2d,f ). Regulatory mutations with scores 2a, 2c and 3b overlapping with peaks in transcription factor chromatin immunoprecipitation and sequencing (ChIP-seq) identified binding sites with matching motifs. We subcategorized these mutations by transcription factor and computed the enrichment in actual compared to simulated mutations. All sites that passed significance (false discovery rate (FDR) < 0.001) in the combined analysis of all cancer types in both the a n a ly s i s npg a n a ly s i s test and validation sets are shown in Figure 2g . There were numerous categories of mutations that were enriched, indicating positive selection in cancer, and few categories that were depleted and thus negatively selected. Clustering of transcription factors by the extent of shared binding sites identified clusters of factors with a high number of shared sites and similar enrichment patterns ( Supplementary Fig. 3b ). These clustered transcription factors were often related family members. Mutations in the binding sites of CEBP factors were highly enriched and significant across all cancer types (P < 1 × 10 −10 , twosided Fisher's exact test). CEBP factors are involved in both gene activation and repression 14 ; thus, mutation of CEBP sites likely alters transcriptional regulation. To further analyze mutations within transcription factor motifs, we systematically aligned the sequences surrounding each mutation with published transcription factor position weight matrices (PWMs) ( Fig. 3a) . For each mutation, we generated a random mutation in the PWM with base conversion probabilities matching those in the original patient sample. We then computed a match score for the reference, observed mutant and random mutant sequences with respect to the motif PWM. Two examples of aligned mutations are shown for CEBPD and SPI1 in Figure 3b . CEBPD binding site mutations were concentrated at the central CG dinucleotide in the palindromic CEBPD motif. In contrast, SPI1 binding site mutations were spread across the entire motif. The pattern of CEBPD binding site mutations is highly suggestive of selection for mutation of a specific residue of the motif. This selection might more effectively inhibit transcription factor binding, increase affinity of the transcription factor for the motif or allow the creation of a new motif. We favor the possibility that mutations in CEBP sites modulate but do not destroy the specificity of these sites, as many of the mutations did not decrease the matching of the motif to PWMs from the literature and previous reports showed that a CEBP binding site matching the mutant version identified here drove transcription in luciferase reporter assays 15 .
Analysis of the motif match scores for the mutant sequences of all transcription factors in comparison to reference sequences showed that, for the majority of transcription factors, the mutated sites significantly reduced the match score ( Fig. 3c) . Comparison of scores to those obtained for randomly mutated motifs showed that six of the transcription factors (GATA3, GATA6, MAFK, FOS, AP-1 and NFE2) had mutated sites with match scores significantly worse than with randomly generated mutated sites (P < 0.001, two-sided paired Wilcoxon rank-sum test; Fig. 3d ). For these factors, the distributions of the deviance for the real and random mutations in these transcription factor sites are shown in Figure 3e , and the identity of these transcription factors and the mean deviance of their scores from those for reference and random sites are shown in Figure 3f . Mutations in the binding sites for these factors tended to be concentrated at one or a few bases of the motif, suggesting selective pressure for these specific mutations (Supplementary Fig. 4f ). All six of these transcription factors have known roles in cancer. GATA3 and GATA6 belong to npg a n a ly s i s the GATA family of transcription factors, which are often lost during advanced carcinogenesis 16 . MAFK belongs to the small MAF protein family and can form heterodimers with CNC transcription factors, including NFE2, and their expression is often lower in cancer 17 . FOS transcription factors as well as MAF family proteins are components of various AP-1 transcription factor complexes, which are canonically thought to promote proliferation and survival in cancer but in certain contexts may also have tumor-suppressor activity 18 . Overall, these results indicate recurrent patterns of mutation in specific transcription factor sites that may either enhance or repress gene expression.
Given the uneven distribution of mutations within the binding sites of a number of transcription factors, we investigated the possibility that specific mutations within these sites might create de novo binding sites for other factors. We focused our attention on the highly significant enrichment of mutations in sites of the CEBP transcription factors and screened known binding site motifs for ones having significantly higher match scores with the mutant CEBP sites than with the reference sites. We found that the mutated sites had higher match scores than the reference sites for SOX17, DBP, SOX10, SOX5, HOXA10, PAX5, CMAF, PARP, EN1, BCL6 and CAP PWMs (Supplementary Fig. 4a ). Alignment of the mutant sequences identified a consensus motif ( Supplementary Fig. 4b) , with the most common instances of this motif shown in Supplementary Figure 4c . The mutated CEBP sites tended to be evenly distributed among all patients, with the exception of one patient with uterine corpus endometrial carcinoma (UCEC), who had many more such mutations than the other patients (Supplementary Fig. 4d) . Expression of the transcription factors corresponding to the high-scoring motifs was not significantly different between samples with and without mutations in these sites (Supplementary Fig. 4e) . These results suggest that selective pressure exists in cancer to convert CEBP sites into a common oncogenic Figure 3 Effects of mutations on transcription factor binding sites. (a) A schematic is shown of the methodology of aligning sequences and generating match scores for mutations contained within transcription factor (TF) binding sites. (b) Reference binding regions at mutated sites for each transcription factor were aligned to the factor's PWM, and sequence logos were generated. Sequence logos for the literature motif, the aligned reference and the aligned mutant sequences as well as the mutation counts at each position are shown for two representative transcription factors (CEBPD and SPI1). (c) For each transcription factor, the match score to the transcription factor PWM was determined for all the factor's mutated sites. Plotted for each transcription factor (x axis) is the mean difference in the match scores for the mutated and reference sites (y axis). Red indicates FDR < 0.05. P value for difference in mean match score was computed by two-sided paired Wilcoxon rank-sum test. (d) Breakdown of transcription factors into those having mutated sites with match scores significantly different from the reference match score and/or significantly different from the match scores of random mutations.(e) A histogram of pooled match scores for transcription factor sites with match scores for real mutations significantly worse than both the corresponding reference and random mutation match scores. (f) For each transcription factor with mutant binding sites having significantly worse match scores than the reference and random mutation match scores, the mean difference between the match scores for the mutant sites and the reference (x axis) is plotted against the mean difference in the match scores for the mutant sites and the random mutant sites (y axis). The color of the text scales with the −log 10 (P value) corresponding to the significance of the difference between the real and random scores, and point size scales with the number of mutant sites. npg a n a ly s i s site; however, it remains unclear whether any factors (either CEBP or alternative factors) bind these new sites.
Recurrently mutated specific regulatory sites
We next sought to further investigate the possibility that a subset of recurrent mutations exist owing to positive selection in cancer. Previous evidence for this phenomenon comes from the identification of somatic mutations upstream of the TERT gene encoding telomerase reverse transcriptase 5, 6 and somatic mutations in regulatory regions of PLEKHS1, WDR74 and SDHD 7 , as well as examples of germline mutations such as those found in the CCND1 enhancer 19 . Previous methodologies for whole-genome analysis of recurrent mutations did not take into account sample-specific probabilities dependent on replication timing, base-pair composition and presence of annotated transcripts-covariates suggested by previous work to affect background mutation rate and model performance 11 . Our algorithm employed logistic regression to determine samplespecific and covariate-corrected background mutation probabilities followed by a Poisson binomial model to account for patient-specific probabilities (Fig. 4a) . We trained our logistic regression model on all mutations from all samples and used the resulting model to estimate the probability of mutation for any particular sample given any combination of replication timing, base-pair type and transcript region. Box plots of these predicted probabilities for all samples and all combinations of covariates showed that base-pair composition and replication timing but not transcript region strongly influence the predicted mutation probabilities (Supplementary Fig. 5a ).
We evaluated all mutated genomic loci for recurrent mutation of both single nucleotides and 10-bp windows around identified mutations. Mutations that were potential false positives from mapping errors or represented common SNPs were removed from the analysis, and multiple-hypothesis testing was conducted by applying a 5% FDR cutoff with the Benjamini-Hochberg procedure 20 . The total number of regions tested for the FDR cutoff was estimated as the average total number of positions in the genome with high read coverage. Results are plotted for both single nucleotides ( Fig. 4b ) and 10-bp windows (Fig. 4c) . Selection of driver mutations in coding genes has been studied extensively, and we replicated a number of known findings, including the identification of selected mutations in the coding regions of TP53, AKT1, PIK3CA, PTEN, EGFR, CDKN2A and KRAS (Fig. 5) . In addition to previously identified TERT promoter mutations, we found eight new mutated loci potentially regulating known cancer-associated genes, including GNAS, INPP4B, MAP2K2, BCL11B, NEDD4L, ANKRD11, TRPM2 and P2RY8. npg a n a ly s i s GNAS, NEDD4L, BCL11B and ANKRD11 are recurrently mutated in cancers 3 . TRPM2 and INPP4B are in the tumor-suppressor database 21 . Additionally, GNAS, MAP2K2, BCL11B and P2RY8 are in the Cancer Gene Census 22 . Our search for recurrent regulatory mutations is related to those of Fredriksson et al. 8 and Weinhold et al. 7 Fredriksson et al. 8 used a cutoff of 5 recurrent mutations in their published list of 17 recurrent promoter mutations. We found the same recurrent mutations in TERT (two sites) and PLEKHS1 (one site). Of the remaining 14 mutations, 12 were in cancer types we did not analyze and 2 were present but below our statistical threshold. If we relaxed the criteria so that mutations were called by both MuTect and VarScan 2, then these two additional sites would also be called. Notably, our method was much more sensitive than the one employing a five-mutation threshold, allowing us to identify many more significantly mutated sites.
In comparison to results from Weinhold et al. 7 , our sites overlapped with mutational hotspot regions near C1orf159, TERT and PLEKHS1. Weinhold et al. 7 used a larger set of tumors and found 193 hotspot regions in promoters and enhancers. We found mutations in our samples in 102 of these regions. Thirty-five of the regions were completely removed from our analysis when accounting for potential mapping errors, and seven additional regions had at least one mutation that was likely a mapping error. Twelve of the 102 regions had counts high enough that they might have been called significant in our analysis if all the mutations had been within 10 bp of each other; however, all but the PLEKHS1 hotspot region had a size greater than 10 bp, and thus our analysis with single nucleotides and 10-bp windows did not result in identification of these sites. In comparison to the method of Weinhold et al. 7 , we found an additional 210 significant single-base recurrently mutated sites that were not in annotated coding regions. These data suggest that our methodology provides substantial gains in both sensitivity and specificity over the method of Weinhold et al. 7 We additionally searched for correlations between 116 mutated regulatory loci and their associated genes, for which matched RNA sequencing (RNA-seq) data were available both for all cancers and each cancer type individually. After multiple-hypothesis correction, one site in proximity to the PLCXD1 gene was significantly correlated with RNA expression (Supplementary Fig. 5c ). This analysis is severely limited by small sample size at any given site and failed to show a correlation even for TERT. In the case of TERT, the trend for increased expression with mutation was present but failed to reach significance after multiple-hypothesis correction. This result is likely due to our limited sample size and the fact that increased TERT expression is driven by mechanisms in addition to promoter mutation in cancer.
Somatic mutation alters enhancer activity
We chose to investigate the functional activity of nine new candidate regulatory mutations as well as four additional regions that were mutated in at least three samples but did not reach significance. One TERT promoter mutation was included as a positive control. We generated luciferase reporter constructs to test the enhancer activity of wild-type and mutated regulatory regions ( Fig. 5a) and screened them in a lung cancer cell line. We found two regions in addition to TERT that had substantial reporter activity relative to the empty vector, and both of these regions showed decreased activity with the mutant versions (Supplementary Fig. 6 ). We investigated these two regions further with the lung cell line and two additional lines (bladder and esophageal). Both mutations in the chromosome 14 region decreased activity in all three cell lines, and the chromosome 19 mutation decreased activity in all but the esophageal cell line. In contrast, the mutant TERT promoter element increased activity in all cell lines (Fig. 5b) . The chromosome 19 mutation is in an intron of the GP6 gene, which currently does not have a well-documented role in cancer. However, the chromosome 14 mutations are situated in a potential enhancer between SETD3 and BCL11B. BCL11B is implicated as a haploinsufficient tumor suppressor in T cell acute lymphoblastic leukemia 23 ; thus, mutations in this element may decrease the activity of BCL11B and contribute to oncogenesis. The GP6 mutated locus can bind ETS1, GAPBP1, POLR2A, SIN3A and EGR1, and the mutated site falls on the edge of an ESR1 motif. The BCL11B locus can bind IRF1, NFYA, NFYB, SP1, TBP, EGR1, MAX, FOS and POLR2A. It remains unclear which factors may have disrupted binding as a result of the mutations.
DISCUSSION
Noncoding DNA elements comprise the majority of the genome, and the data in this study highlight the importance of these regions and regulatory regions in particular in cancer. Our study shows that mutations in specific categories of regulatory sites undergo positive selection. We observe patterns of mutation that suggest that cancers select for specific mutations that destroy and/or possibly create new binding sites for certain transcription factors. Furthermore, we find evidence for the recurrent mutation of specific regulatory sites, including many in proximity to known cancer-related genes. Two of these new regulatory regions display reduced regulatory activity upon mutation.
We find that, for most cancers, somatic mutations do not globally experience purifying selection in regulatory regions. This finding is in contrast to recent evidence that regulatory regions experience purifying selection at the human population level 24 . A major difference between selection in cancer and selection at the human population level is that, in cancer, only a single cell type is subject to selection whereas, in an organism, selection can occur via dysfunction of any cell type. Furthermore, in cancer, damaging mutations may be more tolerated owing to dysfunction in the normal apoptotic process. Previous studies, including those of Weinhold et al. 7 , show that the rate of mutation in intergenic regions is greater than in coding and regulatory regions. Our analysis suggests that the observed differences in mutation rate can be explained largely, if not entirely, by potential false positive mutations from mapping errors and by differences in mutation rate relating to base-pair type and replication timing. Nevertheless, our study is not without important caveats. Our results were generated using regulatory information collected from many cell types. Because only a fraction of annotated regulatory regions are active in any given cell type, the mixture of regulatory and non-regulatory regions may be skewing our results. Indeed, recent data from Polak et al. 25 show that the intrachromosomal mutation rate in cancer is inversely related to the open chromatin state of the cell type of origin for each cancer type but not for other cell types. This finding is consistent with purifying selection occurring only in the subset of regulatory regions active in the cell type of origin for the cancer.
Further subclassification of regulatory mutations by transcription factor binding site identified a subset of regulatory regions that are selectively mutated likely to either destroy the site or increase the affinity of the site for transcription factor binding. Presumably, such mutations could promote cancer by repressing tumor suppressors or by activating oncogenes. Mutations could inactivate tumorsuppressor genes by removing activating sites or adding repressive sites and could activate oncogenes by removing repressive sites or adding activating sites.
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Our study also highlights the potential importance of regulatory driver mutations at specific genomic loci in cancer progression. We find that, in addition to the well-known TERT promoter mutations, there exist a number of regulatory mutations that are positively selected in cancer. Our study implicates a number of regulatory regions in proximity to known cancer-associated genes. Recurrent mutations occur near GNAS, INPP4B, MAP2K2, BCL11B, NEDD4L, ANKRD11, TRPM2 and P2RY8, which are known to be involved in cancer, as well as near genes newly implicated in cancer, such as GP6. These analyses mark an advance toward identifying recurrent functional regulatory region mutations. In the future, incorporation of additional cancer samples from a greater number of cancer types will enable a more comprehensive analysis of shared and cancer typespecific regulatory driver mutations.
It has been suggested that there are as many or more genomic regions responsible for gene regulation than genes themselves 4 . As such, a large number of these regions could be mutated in cancer. This regulatory redundancy may protect against selection for deleterious mutations in the regulatory regions of some tumor suppressors but should also increase the amount of regulatory sequence that could have a functional impact if mutated. The presence of multiple regions upstream of TERT that are implicated in cancer and the fact that any one gene can have numerous different enhancers 26 support this hypothesis. Overall, we expect that many regulatory regions will prove to have important roles in cancer, and the approaches and information employed in this study thus represent a significant advance in the analysis of such regions. 
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METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METHODS
Mutation calling. Access to cancer and normal whole-genome sequencing data was obtained from the TCGA Project via the database of Genotypes and Phenotypes (dbGaP), and raw data were downloaded prealigned in BAM file format from the Cancer Genomics Hub (CGHub). All aligned BAM files were subjected to paired local realignment via RealignerTargetCreator and IndelRealigner in GATK. Base recalibration in the realigned BAM files was then performed using BaseRecalibrator in GATK. Point mutations were called with default settings using MuTect 27 and the VarScan 2 Somatic caller 28 . The intersection of the calls from MuTect and VarScan 2 was used for further analysis.
Regulatory annotations. Mutations were assigned regulatory annotations via RegulomeDB 10 . Regulatory mutations were considered to be any mutation in RegulomeDB categories 1-5, which include all regions that minimally contain a transcription factor binding peak or a DNase I binding peak identified from experimental data.
Transcription factor binding site analysis. PWMs for transcription factors were obtained from Jaspar 29 and Transfac 30 . R code was written to align reference and mutated regions to factor-specific PWMs on the basis of the position of the maximum PWM match score for the transcription factor in the reference sequence. The PWM match score algorithm is taken from Kel et al. 31 . The seqLogo R package was used to display sequence alignments, and the Muscle R package was used to ensure optimal alignment of the transcription factor motifs surrounding mutations. Both the positive and negative (reverse complement) strands of the reference sequence were considered to optimize alignments. For the loss-of-site analyses, the reference sequence surrounding the mutations was used to determine the position of maximal alignment to the transcription factor PWM. For gain-of-site analyses, the mutant sequence was used to identify the position of maximal binding. For the gain-of-site analysis presented in Supplementary Figure 4 , only created sites with a median match score greater than 0.9 were considered. Random mutations in transcription factor binding sites were generated for each binding site mutation in each annotated binding site in each patient. These mutations were selected at random from within the motif, with nucleotide conversion probabilities generated from the overall conversion frequencies for that patient. Figure 2 were generated by overlap of mutations with GENCODE17 transcripts 32 . Mutation location (promoter, 5′ UTR, intron, coding exon, 3′ UTR and gene symbol) annotations in Supplementary Figure 1 were generated using UCSC Gene Annotations 33 . For genes with multiple transcripts, location annotations were assigned in the following order: promoter, coding exon, 5′ UTR, 3′ UTR and intron. For example, if a mutation was in an annotated intron and also in an annotated 3′ UTR, the 3′ UTR annotation was kept and the intron annotation was discarded.
Transcript annotations. Transcript annotations in
Sequencing coverage calculations. Sequencing coverage was calculated from
VarScanSomaticSNP output. This output gives cancer and normal read counts for all potential germline and somatic variants. The median coverage for each cancer and normal sequencing sample was determined by taking the median coverage of these variants.
Covariate-matched simulated mutations. Simulated mutations were generated by first randomly sampling positions in the genome for each patient that could have been called as a mutation on the basis of the MuTect coverage output. Replication timing and base-pair composition covariates were determined for all real and random mutations, and the R Matching package was then used to perform covariate matching for real and random mutations pooled by cancer type.
Splitting of data into experimental and validation sets.
Samples were segregated by cancer type and within each cancer type were sorted by the number of mutations. Walking down the sorted list, the samples were sorted into experimental (E) and validation (V) sets as follows: E, V, V, E, E, V, V, …, E. Replication timing. ENCODE replication timing data were downloaded from the UCSC Genome Browser 34 . The average waveform from the following cell types was used to associate genomic regions with replication timing: BJ, GM06990, GM12801, GM12812, GM12813, GM12878, HeLa-S3, HepG2, HUVEC, IMR-90, K-562, MCF-7, NHEK and SK-N-SH. These averages were then assigned to bins from 1 to 100 to discretize the data.
Statistical modeling of recurrent mutations. All unique chromosomal mutations were tested for statistical significance. Let n be the total number of individuals and k be the number of individuals with a mutation in a particular region. Given a region of interest, we sought to estimate the probability of k or more mutations in n individuals. We used a Poisson binomial model, which differs from the binomial model in that each tumor is assigned its own probability of mutation. Formally, the probability we calculate is as follows:
where F l is the set of all subsets of k integers that can be selected from {1, 2, …, n}, n is the number of tumors, k is the number of tumors with the region mutated, p i is the probability that site i is mutated, p j is the probability that site j is mutated, A is a single set of k integers that can be selected from {1, 2, ..., n} and A c is the complement of this set.
In practice, we used an approximation for the Poisson binomial in the poibin R package 35 . Each individual's unique mutation probability for a given region was determined by fitting a logistic regression model to all data with the following features: patient ID, replication timing bin, base pair (C•G versus A•T), and presence and type (none, coding exon, noncoding exon, coding intron or noncoding intron) of annotated transcripts in the region. Interactions between each patient ID and replication timing, as well as between patient ID and basepair type, were included in the model. These select interactions were included to increase the fit of the model. For regions, as opposed to single sites, the regional probability was determined as follows: where i is the base position within a site of length l and p i is the probability that base i is mutated.
Filtering out false positives from mapping errors and SNPs. SNPs from dbSNP Build 141 were downloaded from the UCSC Genome Browser Table Browser . Called mutations that had the same chromosomal position and variant allele as a common SNP were filtered out. Predicted mapping errors were determined by querying BLAT 36 with a 201-bp region centered on the genomic position of the variant. Notably, the variant allele was used in place of the reference allele for this analysis. A score between 0 and 100 was given on the basis of the length of the longest aligned region for a given BLAT result that included a match of up to100 bp in length to the reference genome such that the reference allele for the matched genomic region matched the called variant allele. A 201-bp window was chosen because it should be sufficiently long to cover all potential overlapping reads, as mapped read sizes are typically smaller than 100 bp. For the analysis using 10-bp windows, a regional score was generated by averaging the scores of all the mutations contained within the region. Regions with an average score of greater than 50 were filtered out as potential false positives. The 1000 Genomes Project hs37d5 reference was used for BLAT searches. The analysis in Supplementary  Figure 1 of overlap between the filtered-out regions and difficult-to-align regions of the genome was performed using 50-mer alignability tracks. Any mutation with a score of 0.5 or less was considered difficult to align.
Luciferase reporter assays. To examine the effects of recurrent somatic mutations on transcription, wild-type and mutant regions of 201 bp in length and centered on the position of each mutation were synthesized and cloned into the KpnI and NheI sites of the pGL4.23[luc2/pmin] luciferase reporter construct (Promega). Lung adenocarcinoma (NCI-H1437), esophageal adenocarcinoma
